Avecho Biotechnology (ASX:AVE) has reached a critical moment in its bid to bring an over-the-counter cannabidiol treatment for insomnia to market, announcing that it has completed recruitment for the interim analysis cohort of its pivotal Phase 3 clinical trial.
The Melbourne-based company has successfully enrolled approximately 210 participants required for the planned interim review of its TPM-enhanced CBD soft gel capsule. The interim analysis, expected in June 2026, will offer the first meaningful indication of the product’s efficacy and help determine the final sample size needed to complete the study.
The Phase 3 trial is designed to support an application to the Therapeutic Goods Administration for registration of the CBD TPM capsule as a treatment for insomnia in Australia. Success would position the company to capitalise on Australia’s over-the-counter CBD pathway, a market projected to exceed US$125 million annually. Beyond Australia, the broader global insomnia market was valued at US$5.22 billion in 2024, underscoring the scale of the commercial opportunity.
Chief Executive Officer Dr Paul Gavin described the completion of recruitment as a significant inflection point for the program, noting that the company is now within sight of long-anticipated efficacy data. He emphasised that the interim results could materially de-risk the development pathway and strengthen Avecho’s hand in ongoing partnership discussions.
Commercial groundwork is already in place. In 2025, Avecho licensed Australian rights to its CBD TPM capsule to Sandoz AG, securing a US$3 million upfront payment and eligibility for up to US$16 million in milestone payments prior to first sales, along with tiered royalties of 14 to 19 per cent on net sales. The company is continuing discussions with potential partners to expand licensing arrangements into other regions.
The clinical study itself is the largest of its kind evaluating cannabidiol for insomnia in Australia. It is a multicentre, randomised, double blind, placebo-controlled trial assessing nightly doses of 75 mg or 150 mg of CBD against placebo over eight weeks. Participants record sleep duration and quality using validated questionnaires and daily sleep diaries, with the study designed to meet regulatory expectations in Australia, the United States and Europe.
Insomnia remains a widespread and economically significant health burden. Globally, between 10 and 30 per cent of people report symptoms, with up to 15 per cent experiencing chronic insomnia. In Australia alone, the economic cost has been estimated at $19.1 billion, and the federal government has signalled that sleep health should be treated as a national priority.
Avecho’s lead asset leverages its proprietary Tocopheryl Phosphate Mixture drug delivery platform, derived from vitamin E, to enhance the solubility and absorption of active compounds. By improving CBD bioavailability, the company aims to differentiate its product in a competitive and evolving therapeutic landscape.